Amgen Hong Kong

Amgen Hong Kong is a prominent biotechnology company focused on developing innovative human therapeutics. Established in 1980, Amgen is committed to transforming scientific advancements into effective medicines for patients suffering from serious illnesses. The company specializes in a range of therapeutic areas, including oncology, hematology, cardiovascular health, inflammation, bone health, nephrology, and neuroscience. Amgen's portfolio includes well-known treatments such as Epogen and Aranesp for red blood cell stimulation, Neupogen and Neulasta for immune system support, and Enbrel and Otezla for inflammatory diseases. Additionally, Amgen has expanded its offerings with cancer therapies like Vectibix and Kyprolis, as well as treatments for conditions such as high cholesterol and migraine. Recent acquisitions have further enhanced Amgen's range, allowing it to address various rare diseases effectively. Through its dedication to science and innovation, Amgen aims to improve patient outcomes and make a significant impact in the healthcare sector.

17 past transactions

TeneoBio

Acquisition in 2021
TeneoBio is a biotechnology company that specializes in the development of human heavy chain antibodies. It has several products in pre-clinical and clinical development for the treatment of multiple myeloma, prostate cancer, and immune disorders. TeneoBio’s antibody discovery engine is based on UniRat™, a proprietary heavy chain only, human immunoglobulin transgenic rat.

Rodeo Therapeutics

Acquisition in 2021
Rodeo Therapeutics is a drug development company focused on novel enzyme target and biological pathway that play a critical role in tissue repair and regeneration. Rodeo’s initial goal is to develop novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant.

Five Prime Therapeutics

Acquisition in 2021
FivePrime is dis­cov­er­ing and devel­op­ing novel ther­a­peu­tic pro­teins and anti­bod­ies by sys­tem­at­i­cally screen­ing all rel­e­vant pro­teins in the human body to find the best pro­tein for treat­ment of a given clin­i­cal indi­ca­tion. FivePrime’s Pro­Screen Engine enables the rapid pro­duc­tion and screen­ing of all ther­a­peu­ti­cally rel­e­vant pro­teins in medically-​​focused assays at the high­est qual­ity stan­dards in the indus­try. This pow­er­ful approach is the polar oppo­site of the industry’s tra­di­tional “one pro­tein at a time”. The Pro­Screen Engine com­prises the defin­i­tive pro­tein col­lec­tion and screen­ing process for bio­log­ics dis­cov­ery and is unprece­dented in its effi­ciency, qual­ity, and scale. In addi­tion to DBL Investors, investors include Domain Asso­ciates, Ver­sant Ven­tures, Kleiner Perkins Cau­field and Byers, Texas Pacific Group, Health­Cap, and Advanced Tech­nol­ogy Ventures.
Keck Graduate Institute (KGI) is part of the prestigious Keck is one of the few graduate schools exclusively dedicated to the study of biosciences. The school’s graduate programs blend academics with business-oriented approaches to the field.

Otezla

Acquisition in 2019
Otezla® is a prescription medicine approved for the treatment of patients with moderate

BeiGene

Post in 2019
Founded in 2010, BeiGene is a global biotechnology company that discovers and develops innovative oncology treatments and aims to make their medicines more accessible and affordable to cancer patients worldwide. The company has more than 9,200 colleagues globally and administrative offices on three continents, as well as one of the largest oncology research teams in the world. BeiGene continues to expand its broad in-house internal clinical development capabilities to make its therapies more available for patients around the globe. BeiGene’s innovative BTK inhibitor BRUKINSA® (zanubrutinib) has been approved in more than 65 markets as a treatment for various blood cancers, and the company's other internally developed cornerstone medicine, tislelizumab, is currently under review by regulators in the U.S. and the EU for the treatment of advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. The company’s broad and deep pipeline has the potential to address 80 of cancers by incidence. Adjacent to its product portfolio and pipeline, the company also sponsors programs aimed at serving the broader needs of oncology patients, such as a program to raise awareness of mental health resources for people and families affected by cancer.

Darmiyan

Non Equity Assistance in 2017
Darmiyan has developed a novel, proprietary, patent-protected technology called The Virtual Microscope (Software Algorithm). Using a non-invasive routine clinical brain MRI scan, The Virtual Microscope technology looks into the human brain and localizes and quantifies cell distortion (neurodegeneration) in every voxel of brain MRI generating new brain maps. The first clinical product of this technology is BrainSee, an AI-powered algorithm that has completed a successful third-party validation in the US and Canada establishing a remarkable accuracy and consistency for prognosis of mild cognitive impairment. It is built on over 40 years of cutting-edge neuroscience research combined with advanced medical image analysis and AI, and has received official approval from the late Prof. Paul Greengard, Nobel Laureate in Physiology/ Medicine 2000.

immatics biotechnologies

Series E in 2017
immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

SiteOne Therapeutics

Series B in 2017
SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics. They develop products safely, effectively, and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Their lead therapeutic candidates are highly selective inhibitors of a voltage-gated sodium ion channel, Naᵥ1.7, which plays a critical role in the generation and conduction of pain signals.

eHealth Ventures

Corporate Round in 2016
eHealth Ventures is a consortium conceived to provide incubation services to promising early-stage healthcare technology companies in Israel. The Government of Israel offers a unique opportunity for leverage by providing significant financial incentives to incubators assisting technology start-ups capitalizing on Israel's extraordinarily rich talent pool. The next Tender is expected the second half of 2014. eHealth Ventures will apply for an eight-year license under the program. They are seeking qualified individual and institutional investors who would like to participate in this extraordinary, highly leveraged opportunity.

Catherex

Acquisition in 2015
In April 2010, Medigene assigned its development program of oncolytic (cancer-killing) herpes simplex viruses (oHSV), to Catherex, Inc.

Dezima Pharma

Acquisition in 2015
Dezima Pharma B.V. develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia. The company was founded in 2012 and is based in Naarden, the Netherlands.

Micromet

Acquisition in 2012
Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.

Bergamo

Acquisition in 2011
Bergamo facilitates access and provides treatments in key therapeutic fields like onco-hematology, general medicine, and hospital segment.

BioVex

Acquisition in 2011
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

Avidia

Acquisition in 2006
Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California.

Filgrastim and Pegfilgrastim

Acquisition in 2002
Filgrastim and pegfilgrastim are a supportive part of treatment for many patients receiving cancer chemotherapy. Some cancer drugs, in addition to attacking the cancer, destroy the patient's white blood cells, which are extremely important in fighting infection. Consequently, these patients are prone to developing severe, and even life-threatening, infections. Filgrastim and pegfilgrastim restore the number of white blood cells and thus improve their ability to kill infecting micro-organisms.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.